Suppr超能文献

AKT和SRC抑制对人胰腺癌细胞的协同抗癌作用

Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells.

作者信息

Ahn Kang, O Young Moon, Ji Young Geon, Cho Han Jun, Lee Dong Hyeon

机构信息

Department of Physiology, School of Medicine, CHA University, Seongnam, Korea.

Department of Preventive Medicine, School of Medicine, CHA University, Seongnam, Korea.

出版信息

Yonsei Med J. 2018 Aug;59(6):727-735. doi: 10.3349/ymj.2018.59.6.727.

Abstract

PURPOSE

To investigate the effect of combined inhibition of protein kinase B (AKT) and SRC on the growth and metastatic potential of human pancreatic cancer cells.

MATERIALS AND METHODS

AKT and SRC were inhibited using 10-DEBC and PP2, respectively. The expression of their messenger RNAs were down-regulated by specific small interfering RNA (siRNA). Changes in pancreatic cancer cell growth and metastatic potential were determined using a cell viability assay and a xenotransplant model of pancreatic cancer, as well as cell migration and invasion assays. Signal proteins were analyzed by Western blot.

RESULTS

The inhibitors 10-DEBC and PP2 suppressed cell proliferation in a dose-dependent fashion in pancreatic cancer cell lines MIA PaCa-2 and PANC-1. The simultaneous inhibition of AKT and SRC at low concentrations resulted in a significant suppression of cell proliferation. Knockdown of AKT2 and SRC using siRNAs also significantly decreased cell proliferation. In a pancreatic cancer model, combined treatment with 10-DEBC and PP2 also significantly suppressed the growth of pancreatic cancer. Application of 10-DEBC with PP2 significantly reduced the metastatic potential of pancreatic cancer cells by inhibiting migration and invasion. The combined inhibition suppressed the phosphorylation of mTOR and ERK in pancreatic cancer cells.

CONCLUSION

Combined targeting of AKT and SRC resulted in a synergistic efficacy against human pancreatic cancer growth and metastasis.

摘要

目的

研究联合抑制蛋白激酶B(AKT)和SRC对人胰腺癌细胞生长和转移潜能的影响。

材料与方法

分别使用10 - DEBC和PP2抑制AKT和SRC。通过特异性小干扰RNA(siRNA)下调它们信使RNA的表达。使用细胞活力测定、胰腺癌异种移植模型以及细胞迁移和侵袭测定来确定胰腺癌细胞生长和转移潜能的变化。通过蛋白质印迹法分析信号蛋白。

结果

抑制剂10 - DEBC和PP2在胰腺癌细胞系MIA PaCa - 2和PANC - 1中以剂量依赖性方式抑制细胞增殖。低浓度下同时抑制AKT和SRC导致细胞增殖受到显著抑制。使用siRNA敲低AKT2和SRC也显著降低细胞增殖。在胰腺癌模型中,10 - DEBC和PP2联合治疗也显著抑制胰腺癌的生长。10 - DEBC与PP2联合应用通过抑制迁移和侵袭显著降低胰腺癌细胞的转移潜能。联合抑制抑制了胰腺癌细胞中mTOR和ERK的磷酸化。

结论

联合靶向AKT和SRC对人胰腺癌的生长和转移产生协同疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b09/6037593/e60e6f789d98/ymj-59-727-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验